{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-003707","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2025-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.924836+00:00","generated_at":"2026-05-27T08:58:58.243600+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"GT Biopharma doses first patient in Phase 1 trial of GTB-3650 for hematologic malignancies","bullets":["GTB-3650 is a second-generation TriKE using camelid nanobody technology to improve potency and binding affinity.","Phase 1 dose-escalation trial will enroll up to ~14 patients (7 cohorts) with r/r CD33+ AML and MDS.","Initial clinical data from the study expected in 2025.","Trial assesses safety, PK, PD, NK cell expansion, and clinical activity over up to 4 months of treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-003707","json":"https://secwatch.observer/filing/0001493152-25-003707.json","markdown":"https://secwatch.observer/filing/0001493152-25-003707.md","text":"https://secwatch.observer/filing/0001493152-25-003707.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315225003707/0001493152-25-003707-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315225003707/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T08:58:58.243600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}